PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
CCENT/2006/62 - LONZA / CAMBREX
Acquired
Cambrex
Description
currently represents one of the business segments in which Cambrex is to be found, with the Cambrex Assets making up the bio-product and bio-pharmaceuticals business. Cambrex is a diversified, global life sciences company devoted to supplying products and services intended to accelerate and improve the discovery and marketing of human therapies
Acquiring
Lonza
Description
is a company based in Switzerland that serves as the principal holding company of the group of multinational chemical and bio-technology companies active in the life sciences industry. Lonza is registered in the SWX Swiss Exchange (LQNN). The group is active, in particular, in exclusive synthesis and bio-pharmaceuticals, organic fine chemicals and performance chemicals, industrial specialties and polymer intermediates.
Sector
  • Extractive and manufacturing Industries
Activity (NACE)
  • C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Applicable legislation
Art. 9(1)(a) (Law 18)
Notification thresholds
Market share
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description
Notified on 13 December 2006, this merger consists of the acquisition of sole control, by the undertaking Lonza Group Limited ("Lonza"), of assets of Cambrex Corporation (hereafter "Cambrex") that represent its bio-product and bio-pharmaceuticals business (hereafter "Cambrex Assets").
Timeline
2007-01-26
Competition Authority approves Lonza Group Limited´s acquisition of sole control of the Cambrex Corporation´s assets representing its bioproduct and biopharmaceutical business
Click here to see your activities